Asthma treatment so far has been a one-size-fits-most approach.
But some asthma patients may be a step closer to one day receiving treatment that is tailored to their own disease, since lebrikizumab (anti-IL-13), our experimental molecule for patients with moderate-to-severe asthma, moved into late-stage clinical development.